# A Study of BL-M14D1 in Combination With Atezolizumab in Patients With Extensive-stage Small Cell Lung Cancer

> **NCT07654400** · PHASE2 · RECRUITING · sponsor: **Sichuan Baili Pharmaceutical Co., Ltd.** · enrollment: 36 (estimated)

## Conditions studied

- Extensive-stage Small-cell Lung Cancer

## Interventions

- **DRUG:** BL-M14D1
- **DRUG:** Atezolizumab

## Key facts

- **NCT ID:** NCT07654400
- **Lead sponsor:** Sichuan Baili Pharmaceutical Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2026-07-09
- **Primary completion:** 2027-12
- **Final completion:** 2027-12
- **Target enrollment:** 36 (ESTIMATED)
- **Last updated:** 2026-08-25

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07654400

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07654400, "A Study of BL-M14D1 in Combination With Atezolizumab in Patients With Extensive-stage Small Cell Lung Cancer". Retrieved via MORVS 2026-10-20 from https://api.morvs.ai/clinical/NCT07654400. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*